Fox Run Management L.L.C. Purchases New Shares in Repligen Co. (NASDAQ:RGEN)

Fox Run Management L.L.C. bought a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,635 shares of the biotechnology company's stock, valued at approximately $667,000.

Several other hedge funds have also recently bought and sold shares of RGEN. Signaturefd LLC raised its position in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the period. Resources Management Corp CT ADV bought a new position in Repligen in the 3rd quarter worth $37,000. Quarry LP lifted its position in Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 239 shares during the last quarter. UMB Bank n.a. lifted its position in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares during the last quarter. Finally, Global Retirement Partners LLC grew its position in shares of Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 129 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Price Performance

Shares of Repligen stock traded down $3.71 during trading on Friday, hitting $133.41. 856,653 shares of the company's stock traded hands, compared to its average volume of 673,469. The company has a market cap of $7.49 billion, a PE ratio of -261.59, a PEG ratio of 4.54 and a beta of 0.95. The firm's fifty day moving average price is $154.21 and its 200 day moving average price is $148.14. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $184.98. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Evercore ISI initiated coverage on Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective for the company. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. Finally, TD Cowen started coverage on shares of Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, Repligen currently has a consensus rating of "Hold" and a consensus target price of $178.64.

Insider Activity at Repligen

In other news, Director Margaret Pax bought 250 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.20% of the stock is owned by insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.